Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702684 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL18094994 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL31230863 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| Hydrochloric Acid SCHEMBL16703240 | 0.99 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| Hydrochloric Acid SCHEMBL28391503 | 0.99 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| Hydrochloric Acid SCHEMBL18094991 | 0.99 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| Hydrochloric Acid SCHEMBL18094975 | 0.99 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL16703340 | 0.95 | DPP4 (0.54) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL20853463 | 0.95 | DPP4 (0.54) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL16703025 | 0.95 | DPP4 (0.54) | OPRM1OPRD1DPP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4001272-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2024-11-13 | — | — | EP | claimed |
| EP-3564234-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | claimed |
| EP-3066091-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | claimed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |